Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
LL-37
Cathelicidin, Human Cathelicidin Antimicrobial Peptide
An antimicrobial peptide produced by epithelial cells in response to infection and inflammation. Part of the innate immune system's first line of defense. Research interest is growing for its potential in wound healing and anti-biofilm applications.
The only human cathelicidin antimicrobial peptide, LL-37 is a 37-amino-acid peptide naturally produced by immune cells, epithelial cells, and barrier tissues. It plays a critical role in innate immunity by directly killing bacteria, viruses, and fungi, while also modulating inflammatory responses. Increasingly studied for chronic infections, biofilm disruption, and immune regulation.
Disrupts microbial cell membranes through electrostatic interaction with negatively charged phospholipids. Also acts as a chemoattractant for dendritic cells and T-cells, bridging innate and adaptive immunity. Upregulated by IL-1β, TNF-α, and bacterial components.
Disrupts microbial membranes through electrostatic interaction with negatively charged bacterial surfaces, creating pores that kill pathogens. Also modulates immune responses by recruiting immune cells, promoting wound healing, and disrupting bacterial biofilms. Acts as a bridge between innate and adaptive immunity.
- Antimicrobial research
- Wound healing research
- Biofilm disruption
- Immune modulation research
- Immune system support
- Chronic infection management
- Biofilm disruption (Lyme, SIBO)
- Wound healing
- Upper respiratory infection support
- Research compound only — no human clinical use data
- Potential for immune overstimulation
- Stability challenges in formulation
- Cost-prohibitive for therapeutic use currently
- Injection site reactions (pain, redness)
- Potential autoimmune activation at high doses
- Limited human clinical data for therapeutic use
- Overexpression linked to psoriasis and rosacea in some contexts
No FDA regulatory category. Available only as a research reagent. No clinical trials for therapeutic use. Active area of academic research.
Not FDA-approved as a therapeutic. LL-37 is an endogenous human peptide being studied in clinical trials for wound healing and infection. Some compounding pharmacies have offered it, but it has no formal FDA category for compounding. Research is ongoing for topical wound applications.
- Human beta-defensins: an update
2012 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.